Full Press Release Details
Biogen Receives Positive CHMP Opinion for TYSABRI® (Natalizumab) Use in Highly Active RRMS Patients with Inadequate Response to Prior MS Therapy.
BIIB
Biogen Receives Positive CHMP Opinion for TYSABRI® (Natalizumab) Use in Highly Active RRMS Patients with Inadequate Response to Prior MS Therapy
Key Takeaway: Biogen Receives Positive CHMP Opinion for TYSABRI® (Natalizumab) Use in Highly Active RRMS Patients with Inadequate Response to Prior MS Therapy